Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCP NASDAQ:PLRX NASDAQ:PMVP NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.38-0.5%$1.24$0.86▼$2.67$18.96M1.51.74 million shs75,002 shsPLRXPliant Therapeutics$1.23-0.8%$1.29$1.09▼$1.95$76.47M1.2688,366 shs30,526 shsPMVPPMV Pharmaceuticals$1.43+0.4%$1.44$0.81▼$1.88$76.00M1.41530,615 shs53,006 shsRLYBRallybio$14.42-1.7%$9.18$2.16▼$15.31$76.26M-1.1240,697 shs29,814 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma-1.42%-2.80%-5.44%+43.31%-11.46%PLRXPliant Therapeutics+0.81%+1.64%-5.34%+8.77%-13.29%PMVPPMV Pharmaceuticals-2.07%+2.16%+10.08%+36.54%+59.59%RLYBRallybio+0.69%+63.25%+82.11%+208.63%+509.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.38-0.5%$1.24$0.86▼$2.67$18.96M1.51.74 million shs75,002 shsPLRXPliant Therapeutics$1.23-0.8%$1.29$1.09▼$1.95$76.47M1.2688,366 shs30,526 shsPMVPPMV Pharmaceuticals$1.43+0.4%$1.44$0.81▼$1.88$76.00M1.41530,615 shs53,006 shsRLYBRallybio$14.42-1.7%$9.18$2.16▼$15.31$76.26M-1.1240,697 shs29,814 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma-1.42%-2.80%-5.44%+43.31%-11.46%PLRXPliant Therapeutics+0.81%+1.64%-5.34%+8.77%-13.29%PMVPPMV Pharmaceuticals-2.07%+2.16%+10.08%+36.54%+59.59%RLYBRallybio+0.69%+63.25%+82.11%+208.63%+509.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 2.00Hold$6.00333.84% UpsidePLRXPliant Therapeutics 1.80Reduce$3.00143.90% UpsidePMVPPMV Pharmaceuticals 2.50Moderate BuyN/AN/ARLYBRallybio 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest COCP, RLYB, PLRX, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PLRXPliant Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026PMVPPMV Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/13/2026PLRXPliant Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$4.00 ➝ $3.003/12/2026PLRXPliant Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$4.00 ➝ $3.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$0.46 per shareN/APLRXPliant Therapeutics$1.58M48.20N/AN/A$2.95 per share0.42PMVPPMV PharmaceuticalsN/AN/AN/AN/A$1.97 per shareN/ARLYBRallybio$860K88.67N/AN/A$10.98 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$8.83M-$0.79N/AN/AN/AN/A-132.61%-89.83%5/21/2026 (Estimated)PLRXPliant Therapeutics-$149.34M-$2.44N/AN/AN/AN/A-68.71%-51.47%5/11/2026 (Estimated)PMVPPMV Pharmaceuticals-$77.74M-$1.49N/AN/AN/AN/A-59.07%-54.19%5/8/2026 (Estimated)RLYBRallybio-$8.98M-$2.56N/AN/AN/A-1,046.39%-56.93%-52.67%5/12/2026 (Estimated)Latest COCP, RLYB, PLRX, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026N/ACOCPCocrystal Pharma-$0.15N/AN/AN/AN/AN/A5/12/2026Q1 2026RLYBRallybio-$1.20N/AN/AN/A$0.23 millionN/A5/11/2026Q1 2026PLRXPliant Therapeutics-$0.36N/AN/AN/AN/AN/A5/8/2026Q1 2026PMVPPMV Pharmaceuticals-$0.41N/AN/AN/AN/AN/A3/31/2026Q4 2025COCPCocrystal Pharma-$0.18-$0.17+$0.01-$0.17N/AN/A3/16/2026Q4 2025RLYBRallybio-$1.04-$1.03+$0.01-$1.03$0.10 million$0.22 million3/11/2026Q4 2025PLRXPliant Therapeutics-$0.44-$0.35+$0.09-$0.38N/AN/A3/6/2026Q4 2025PMVPPMV Pharmaceuticals-$0.40-$0.34+$0.06-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A3.683.68PLRXPliant TherapeuticsN/A12.0012.00PMVPPMV PharmaceuticalsN/A10.0910.09RLYBRallybioN/A14.5114.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%PLRXPliant Therapeutics97.30%PMVPPMV Pharmaceuticals90.20%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma28.14%PLRXPliant Therapeutics8.00%PMVPPMV Pharmaceuticals7.57%RLYBRallybio10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma1013.79 million9.91 millionNot OptionablePLRXPliant Therapeutics9061.92 million56.96 millionOptionablePMVPPMV Pharmaceuticals5053.33 million49.29 millionOptionableRLYBRallybio405.29 million4.75 millionNot OptionableCOCP, RLYB, PLRX, and PMVP HeadlinesRecent News About These CompaniesAdar1 Capital Management, Llc Acquires 120,804 Shares of Rallybio (NASDAQ:RLYB) StockMay 8 at 5:46 AM | americanbankingnews.comAdar1 Capital Management, Llc Purchases 35,101 Shares of Rallybio (NASDAQ:RLYB) StockMay 8 at 5:04 AM | americanbankingnews.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 35,101 SharesMay 7 at 8:16 AM | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Purchases $491,414.00 in StockMay 6 at 10:11 PM | marketbeat.comRallybio (NASDAQ:RLYB) Major Shareholder Buys $1,687,631.88 in StockMay 6 at 10:11 PM | marketbeat.comRallybio (RLYB) Projected to Post Quarterly Earnings on TuesdayMay 5 at 1:06 PM | marketbeat.comRallybio Receives Termination Fee After Candid Deal CollapseMay 4, 2026 | tipranks.comRallybio CMO Departs Amid Pending Candid Therapeutics MergerMarch 31, 2026 | tipranks.comCandid lists via Rallybio reverse merger, adds $505m financingMarch 5, 2026 | thepharmaletter.comTRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBMarch 4, 2026 | businesswire.comRallybio Corp.March 3, 2026 | marketwatch.comRallybio Corporation and Candid Therapeutics Announce Merger AgreementMarch 2, 2026 | finance.yahoo.comRallybio Corporation (RLYB) M&A Call Prepared Remarks TranscriptMarch 2, 2026 | seekingalpha.comRallybio to Merge with Candid Therapeutics in All-Stock DealMarch 2, 2026 | tipranks.comRLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its ShareholdersMarch 2, 2026 | businesswire.comRallybio Announces Reverse Stock Split of Common StockFebruary 3, 2026 | businesswire.comRallybio Shareholders Approve Reverse Stock Split AmendmentJanuary 31, 2026 | theglobeandmail.comRallybio Terminates Phase 2 FNAIT Pregnancy Study: What Investors Need to KnowJanuary 13, 2026 | tipranks.comRallybio’s Phase 2 FNAIT Prevention Study Reaches Completion: What Investors Should Watch NextJanuary 9, 2026 | tipranks.comRallybio Corporation Reports Strong Q3 2025 ResultsNovember 6, 2025 | tipranks.comRallybio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 6, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, RLYB, PLRX, and PMVP Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.38 -0.01 (-0.50%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Pliant Therapeutics NASDAQ:PLRX$1.23 -0.01 (-0.81%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.PMV Pharmaceuticals NASDAQ:PMVP$1.42 +0.01 (+0.35%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Rallybio NASDAQ:RLYB$14.42 -0.25 (-1.67%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
